DOCSLIB.ORG

Book of Abstract 2008

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Book of Abstract 2008 Co-chairs of the conference: Janko Kos, Faculty of Pharmacy, University of Ljubljana, Slovenia Gregor Serša, Institute of Oncology, Ljubljana, Slovenia Tamara Lah Turnšek, National Institute of Biology, Ljubljana, Slovenia Scientific committee: Janko Kos, Rolf Bjerkvig, Maria Grazia Daidone, Dylan Edwards, Tamara Lah Turnšek, Eberhard Neumann, Christoph Peteres, Gregor Serša, Bonnie Sloan, Gillian M. Toz e r Sponsored by: AstraZeneca UK Limited, Branch Office in Ljubljana Amgen Drugs d.o.o., Ljubljana Carl Zeiss d.o.o., Ljubljana CSC Pharma d.o.o., Ljubljana Educell d.o.o., Ljubljana Elex Unitrade, Ljubljana IGEA S.r.l., Carpi Janssen-Cilag Slovenia, Division of Johnson & Johnson d.o.o., Ljubljana Kemomed, d.o.o., Kranj Krka, d.d., Novo mesto Labormed d.o.o., Ljubljana Lek a Sandoz Company, Ljubljana LKB Vertriebs Ges.m.b. H., Wien Medias International d.o.o., Ljubljana Mediline d.o.o., Kamnik Merck d.o.o., Slovenija Mikro+Polo d.o.o., Maribor Olympus Slovenija d.o.o., Ljubljana Pivovarna Laško d.d., Laško Roche Pharmaceutical Division d.o.o., Ljubljana Sanolabor d.d., Ljubljana Santomas, Šmarje Schering-Plough CE EG, Branch Office in Ljubljana Slovenian Research Agency, Ljubljana BOOK OF ABSTRACTS Editors: Gregor Serša, Janko Kos, Tamara Lah Turnšek, Simona Kranjc, Zala Jevnikar, Nataša Obermajer Issued by: Association of Radiology and Oncology Design: Maja Licul, Simona Kranjc Printed by: Solas d.o.o CIP - Kataložni zapis o publikaciji Narodna in univerzitetna knjižnica, Ljubljana 616-006(063) CONFERENCE on Experimental and Translational Oncology (5; 2008; Kranjska gora) Book of Abstracts - 5th Conference on Experimental and Translational Oncology, Kranjska gora, Slovenia, March 26-30, 2008; [editors: Gregor Serša, Janko Kos, Tamara Lah Turnšek, ISBN 978-961-91302-2-3 Simona Kranjc, Zala Jevnikar, Nataša Obermajer] -Ljubljana: 1. Serša Gregor Association of Radiology and Oncology, 2008 238036736 BOOK OF ABSTRACTS 5th Conference on Experimental and Translational Oncology Kranjska gora, Slovenia March, 26-30, 2008 Table of Contents Conference Programme 5 Abstract of Lectures 11 Abstract of Posters 79 List of Participants 132 Author Index 143 Sponsors 148 Conference Programme Wednesday, March 26, 2008 13.00 – 18.30 Conference Registration 17.00 – 17.30 Opening of the Conference 17.30 – 18.30 Opening Lecture Chair: Gregor Serša Malcolm Reed: Genetic predisposition to breast cancer- clinical perspectives 18.30 – 19.30 Reception 20.30 – 21.30 Dinner Thursday, March 27, 2008 8:30 – 10:20 Section 1: Carcinogenesis Chairs: Metka Filipič & R. Schulte Hermann 8:30 – 8:55 Radovan Komel: Protein microarray approach in tumour biology investigation 8:55 – 9:15 Metka Filipič: Cancer preventive potential of xantohumol from hop (Humulus lupulus L.) 9:15 – 9:40 R. Schulte Hermann: Pro-carcinogenic effects of non-genotoxic- chemical carcinogens 9:40 – 10:05 Lisa Wiesmüller: Resveratrol induces fidelity control mechanisms of DNA double-strand break repair via activation of ATM/ATR signalling pathways 10:05 – 10:20 Krešimir Pavelić: The role of integrative genomics/proteomics in the detection and treatment of metastatic breast cancer 10:20 – 10:45 Break 10:45 – 13:10 Section 1: Carcinogenesis (Continued) Chairs: Edward Dylan & Janko Kos 10:45 – 11:10 Edwards Dylan: ADAM (a disintegrin and metalloproteinase) proteases as potential cancer therapeutic targets 11:10 – 11:35 Jürgen Dittmer: Cox-2 is a target gene of Rho GDP dissociation inhibitor β in breast cancer cells 11:35 – 12:00 Muschel Ruth: Mechanisms in metastasis 12:00 – 12:25 Verena Amberger Murphy: Tyrosine kinase inhibitors increase the anti-tumour effect of chemotherapy drugs in malignant gliomas 12:25 – 12:40 Tomaž Langerholc: Monomerisation of cystatin F: who’s in charge? 5 12:40 – 12:55 Irina Kondakova: Matrix metalloproteinases, their tissue inhibitors and progression of head and neck squamous carcinoma 12:55 – 13:10 Martin Illeman: The expression pattern of the urokinase plasminogen activation system in human colon cancer is recapitulated in liver metastases with desmoplastic encapsulation 13:10 – 15:00 Lunch 15:00 – 16:40 Section 2: Mechanisms of Tumour Progression Chairs: Margareta Muller & Ron van Noorden 15:00 – 15:25 Margareta Müller: Inflammation, angiogenesis and tumor invasion: the role of proteolytic enzymes in the malignant progression of skin SCCs 15:25 – 15:50 Ron van Noorden: A glioblastoma-specific kinase expression profile 15:50 – 16:15 Charlotte Kopitz: Cooperation of urokinase-type plasminogen activator and tissue inhibitor of metalloproteinases-1 in the creation of a pro-metastatic niche via hepatocyte growth factor-signalling in the liver 16:15 – 16:40 Olga Vasiljeva: Reduced tumour cell proliferation and delayed development of high grade mammary carcinomas in cathepsin B deficient mice 16:40 – 17:00 Break 17:00 – 19:10 Section 2: Mechanisms of Tumour Progression (Continued) Chairs: Boris Turk & Katarina Wolf 17:00 – 17:25 Katarina Wolf: Mechanisms of proteolytic tumor invasion resulting in multicellular tumor patterning 17:25 – 17:50 Tamara Lah Turnšek: Altered expression of cysteine cathepsins and matrix metallo-proteases (MMP2 and MMP9) in brain tumors differentially affect glioma progression 17.50 – 18.15 Boris Turk: Lysosomal protease-mediated killing of cells: possible use in cancer therapy? 18.15 – 18.40 Irena Mlinarič Raščan: The pharmacogenetic basis for individualized thiopurine therapy 18.40 – 18.55 Zala Jevnikar: Cathepsin X controls migration and invasiveness of T lymphocytes 18:55 – 19:10 Natalia Sharova: The role of the immune proteasomes in the anticancer defence 19:10 – 20:30 Dinner 20:30 – 22:00 Poster Session I 6 22:00 Social Event Friday, March 28, 2008 8.30 – 13.00 Social Events & Personal Communication 13.00 – 15.00 Lunch 15.00 – 16.30 Parallel Sections 3 and 4 Section 3: Tumour Markers Chairs: Janko Kos & Maria Grazia Daidone 15:00-15:25 Maria Grazia Daidone: Markers predicting clinical outcome in breast cancer patients treated with anti-estrogen therapy: towards the identification of biologically and clinically relevant information 15:25 – 15:50 Angelo Paradiso: Reproducibilty of Her-/2neu analysis: analytical and clinical implications 15:50 - 16:15 Paule Opolon: Immunohistochemistry in oncology : a tool for diagnosis, prognosis and treatment 16:15 - 16:30 Julie Decock: Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis Section 4: Stem Cells in Cancer Chairs: Tamara Lah Turnšek & Christian Schichor 15:00 - 15:25 Christian Schichor: Interaction of human adult mesenchymal stem cells and malignant gliomas 15:25 - 15:50 Nataša Levičar: Adult stem cells: from bench to bedside 15: 50 - 16:05 Ketai Guo: Aptamer-based capture molecules as a novel method to isolate porcine mesenchymal stem cells 16:05 – 16:20 Laura Gribaldo: Stem cells in toxicology 16:20 – 16:35 Uroš Rajčevič: Addressing the angiogenic switch by studying tumor- host interactions in an animal model of glioblastoma multiforme 16:30 – 17:00 Break 17:00 – 19:05 Parallel Sections 3 and 5 Section 3: Tumour Markers (Continued ) Chairs: Manfred Schmitt & Gunilla Høyer Hansen 17:00 – 17:25 Manfred Schmitt: Kallikrein-related peptidases: novel therapeutic target molecules 17:25 – 17:50 Gunilla Høyer Hansen: Clinical use of cleaved forms of the urokinase receptor 17:50 – 18:15 Primož Strojan: Cysteine cathepsins and stefins in head and neck cancer: an update of clinical studies 7 18:15 – 18:40 Ib Jarle Christensen: Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4990 patients 18:40 – 19:05 Engin Ulukaya: Chemotherapy-induced cell death and its assessment in vivo Section 5: Delivery Systems in Cancer Therapy I Chairs: Gregor Serša & Lluis Mir 17:00 – 17:25 Eberhard Neumann: Kinetics of tumour growth and of vascular perfusion flow in electrochemotherapy 17:25 – 17:50 Lluis Mir: Tumor ablation with irreversible electroporation 17:50 – 18:15 Muriel Golzio: Gene expression regulation by siRNA electrotransfer 18:15 – 18:40 Justin Teissié: Time dependence of electric field effects on cell membranes 18:40 – 19:05 Nataša Pavšelj: Numerical modelling in electroporation-based biomedical applications 19:05 – 20:30 Dinner 20:30 – 21:00 Commercial presentation Gianpaolo Milite: Specific laboratory animal husbandry in oncologic research 21:00 – 22:00 Poster Session II Saturday, March 29, 2008 8:30 – 10:30 Section 5: Delivery Systems in Cancer Therapy Chairs: Maja Čemažar & Eberhard Neumann 8:30 – 8:55 Elena Reddi: Photosensitizer-loaded nanoparticles for improving the efficacy and selectivity of photodynamic therapy of tumours 8:55 – 9:20 Youssef Tamzali: Electrochemotherapy in veterinary oncology 9.20 – 9:45 Maja Čemažar: Cancer gene therapy by electrotransfer of nucleic acids into tissues 9:45 – 10:00 Gregor Tevž: IL-12 gene therapy of murine sarcoma tumors and metastases combined with radiotherapy 10:00 – 10:15 Nataša Obermajer: The use of immuno-nanoparticles for impairment of intracellular proteolytic activity in invasive breast tumor cells 10:15 – 10:45 Break 8 10:45 – 13.00 Section 6: New Drugs and Therapeutic Targets Chairs: Carlos Lopez Otin & Agnes Noel 10:45 – 11.10 Carlos Lopez Otin: Proteases in cancer: progression or protection? 11:25 – 11:50 Agnes Noel: The lymphatic ring assay: a new in vitro model of lymphangiogenesis 11:50 – 12:15 Chryso Kanthou: Tumour vascular disrupting agents: mechanism of action 12:15 – 12:40 Jozef Timar: Melanoma genomics and molecular targeting 12:40 – 12:55 Stanislav Gobec: New inhibitors of steroid metabolizing enzymes as potential anticancer drugs 13.00 – 15. 00 Lunch 15.00 – 16.55 Section 5: Delivery Systems in Cancer Therapy (Continued) Chairs: Gillian M. Tozer & Boris Vojnović 15:00 – 15:25 Boris Vojnović: Towards high throughput, high content, fluorescence lifetime imaging 15:25 – 15:50 Barbara Pedley: Effect of the tumour microenvironment on targeted therapies 15:50 – 16:15 Gregor Serša: Vascular disrupting action of electroporation and electrochemotherapy 16:15 – 16:40 Gillian M.
Load more

Recommended publications
  • Up-Regulation of Bax and Endonuclease G, and Down-Modulation of Bcl-XL Involved in Cardiotoxin III-Induced Apoptosis in K562 Cells
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 38, No. 4, 435-444, August 2006 Up-regulation of Bax and endonuclease G, and down-modulation of Bcl-XL involved in cardiotoxin III-induced apoptosis in K562 cells Sheng-Huei Yang1, Ching-Ming Chien1, Keywords: apoptosis; bcl-2-associated X protein; car- Mei-Chin Lu2, Yi-Hsiung Lin1, diotoxin III, Naja naja atra; caspase; endonuclease G; Xiu-Wei Hu1 and Shinne-Ren Lin1,3 K562 cells 1Faculty of Medicinal and Applied Chemistry 2 Introduction Graduate Institute of Natural Products Kaohsiung Medical University Many therapeutic and chemopreventive agents Kaohsiung 807, Taiwan, ROC 3Corresponding author: Tel, 886-7-3121101#2219; eliminate cancerous cells by inducing programmed Fax, 886-7-3123443; E-mail, [email protected] cell death (apoptosis) (Kaufmann et al., 2000; Ro- bertson et al., 2000). Apoptosis is an important Accepted 24 July 2006 cellular process for destruction of undesirable cells during development or homeostasis in multi-cellular Abbreviations: CTX III, Carditoxin III; MTT, 3-(4,5-dimethylthia- organisms. This process is characterized by distinct zol-2-yl)-2,5-diphenyltetrazolium bromide; PARP, poly (ADP-ribo- morphological changes including plasma membrane se) polymerase; Z-VAD-FMK, benzyloxycarbonyl-Val-Ala-Asp- bleb, cell shrinkage, depolarization of mitochondria, fluoromethylketone chromatin condensation, and DNA fragmentation (Kaufmann et al., 2001; Reed, 2001). Caspases are essential for the execution of cell death by various Abstract apoptotic stimuli (Cohen, 1997; Shi, 2002). Caspase activation is often regulated by various cellular pro- Cardiotoxin III (CTX III), a basic polypeptide with 60 teins including members of the IAP (Deveraux and amino acid residues isolated from Naja naja atra Reed, 1999) and Bcl-2 families (Adams and Cory, venom, has been reported to have anticancer activity.
    [Show full text]
  • Coumarin Induces Cell Cycle Arrest and Apoptosis in Human
    in vivo 21: 1003-1010 (2007) Coumarin Induces Cell Cycle Arrest and Apoptosis in Human Cervical Cancer HeLa Cells through a Mitochondria- and Caspase-3 Dependent Mechanism and NF-κB Down-regulation JING-YUAN CHUANG1, YUNG-FENG HUANG1, HSU-FENG LU2, HENG-CHEN HO3, JAI-SING YANG4, TE-MAO LI5, NAI-WEN CHANG3 and JING-GUNG CHUNG6,7 Departments of 1Medical Laboratory Science and Biotechnology, 3Biochemistry, 4Pharmacology and 6Microbiology, 7School of Biological Science and Technology, and 5Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan; 2Department of Clinical Pathology, Cheng Hsin Rehabilitation Medical Center, Taipei, Taiwan, R.O.C. Abstract. The effects of coumarin on cell viability, cell cycle investigators have also reported on the use of coumarin (1,2- arrest and induction of apoptosis were investigated in human benzopyrone), or its metabolite 7-hydroxycoumarin, for the cervical cancer HeLa cells. Coumarin was cytotoxic with an treatment of some human carcinomas (4-7). No adverse effects of coumarin have been reported in humans using doses up to IC50 of 54.2 ÌM, induced morphological changes, and caused G0/G1 arrest and apoptosis. The decreasing number of viable 7 g daily, after two weeks of continued treatment (8, 9). In the cells appeared to be due to induction of cell cycle arrest and present study, the effect of coumarin on cell cycle arrest and apoptotic cell death, since coumarin induced morphologically induction of apoptosis in human cervical cancer HeLa cells, for apoptotic changes and internucleosomal DNA laddering which no information is currently available, was examined. fragmentation and increased the sub-G1 group.
    [Show full text]
  • Serial Profiling of Cell-Free DNA and Nucleosome Histone Modifications
    www.nature.com/scientificreports OPEN Serial profling of cell‑free DNA and nucleosome histone modifcations in cell cultures Vida Ungerer1,3, Abel J. Bronkhorst1,3, Priscilla Van den Ackerveken2, Marielle Herzog2 & Stefan Holdenrieder1* Recent advances in basic research have unveiled several strategies for improving the sensitivity and specifcity of cell‑free DNA (cfDNA) based assays, which is a prerequisite for broadening its clinical use. Included among these strategies is leveraging knowledge of both the biogenesis and physico‑chemical properties of cfDNA towards the identifcation of better disease‑defning features and optimization of methods. While good progress has been made on this front, much of cfDNA biology remains uncharted. Here, we correlated serial measurements of cfDNA size, concentration and nucleosome histone modifcations with various cellular parameters, including cell growth rate, viability, apoptosis, necrosis, and cell cycle phase in three diferent cell lines. Collectively, the picture emerged that temporal changes in cfDNA levels are rather irregular and not the result of constitutive release from live cells. Instead, changes in cfDNA levels correlated with intermittent cell death events, wherein apoptosis contributed more to cfDNA release in non‑cancer cells and necrosis more in cancer cells. Interestingly, the presence of a ~ 3 kbp cfDNA population, which is often deemed to originate from accidental cell lysis or active release, was found to originate from necrosis. High‑resolution analysis of this cfDNA population revealed an underlying DNA laddering pattern consisting of several oligo‑ nucleosomes, identical to those generated by apoptosis. This suggests that necrosis may contribute signifcantly to the pool of mono‑nucleosomal cfDNA fragments that are generally interrogated for cancer mutational profling.
    [Show full text]
  • DNA Laddering Nonbook
    ® Apoptotic Cell DNA Laddering Kit For detection of double-stranded DNA breaks in apoptotic cells Catalog No. 30-1231, 20 tests Instructions Store at 15 to 30°C. For laboratory research use only. Not for human, clinical, or diagnostic use. American Type Culture Collection 800-638-6597 or 703-365-2700 P.O. Box 1549 Fax: 703-365-2750 Manassas, VA 20108 USA E-mail: [email protected] www.atcc.org Or contact your local distributor. TABLE OF CONTENTS Introduction Background ............................................................................... 2 References ............................................................................... 2 Precautions ............................................................................... 2 Kit Components ................................................................................. 3 Materials Required But Not Supplied ................................................ 3 Protocols Experimental Outline ................................................................ 4 Isolation of DNA from Cells in Culture ...................................... 4 Gel Electrophoresis .................................................................. 5 Data Interpretation ............................................................................. 6 Appendix DNA Quantitation ....................................................................... 6 Reagent Preparation ................................................................ 7 Gel Preparation ........................................................................
    [Show full text]
  • Instructions TACS Apoptotic DNA Laddering
    IFU0202 Rev 0 Status: RELEASED printed 12/9/2016 11:34:42 AM by Trevigen Document Control Instructions For Research Use Only. Not For Use In Diagnostic Procedures TACS® Apoptotic DNA Laddering Kit Protocol Covers the Following: Cat# 4850-20-ET Ethidium Bromide 20 reactions Cat# 4859-20-K Tissue Supplement 20 reactions E5/20/10v1 i IFU0202 Rev 0 Status: RELEASED printed 12/9/2016 11:34:42 AM by Trevigen Document Control TACS® Apoptotic DNA Laddering Kit Cat# 4850-20-ET Cat# 4859-20-K Table of Contents Page I. Background 1 II. Precautions and Limitations 1 III. Materials Supplied 1 IV. Materials Required But Not Supplied 2 V. Reagent Preparation 2 VI. Assay Protocols 2 VII. Interpretation 5 VIII. Casting TreviGel™ 500 5 IX. Troubleshooting Guide 6 X. References 6 XI. Related Products Available From Trevigen 7 ©2010 Trevigen, Inc. All rights reserved. Trevigen, Cultrex, TACS•XL, and TACS are registered trademarks, and TreviGel, is a trademark of Trevigen, Inc. E5/20/10v1 i IFU0202 Rev 0 Status: RELEASED printed 12/9/2016 11:34:42 AM by Trevigen Document Control I. Background Trevigen's TACS® Apoptotic DNA laddering kit is used to assay cells and tissues for apoptosis by detecting double-strand breaks in genomic DNA and determining the level of DNA degradation. DNA fragmentation is considered to be irreversible, and a classical indicator of apoptosis. During apoptosis, DNA is cleaved between the nucleosomes into 180-200 bp fragments. These DNA fragments are analyzed by horizontal gel electrophoresis followed by ethidium bromide staining. When analyzing tissue samples, it is necessary to disrupt the tissue and create a cell suspension.
    [Show full text]
  • DNA Fragmentation Into 200-250 And/Or 30-50 Kilobase Pair Fragments in Rat Liver Nuclei Is Stimulated by Mg2+ Alone and Ca2’/Mg2’ but Not by Ca2+ Alone
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 349 (1994) 385-391 FEBS 14321 DNA fragmentation into 200-250 and/or 30-50 kilobase pair fragments in rat liver nuclei is stimulated by Mg2+ alone and Ca2’/Mg2’ but not by Ca2+ alone Kelvin Cain*, Salmaan H. Inayat-Hussain, James T. Wolfe, Gerald M. Cohen MRC Toxicology &ii, Hodgkin Building, University of Leicester, PO Box 138, Loneaster Rd., Leicester LEl 9HN, UK Received 31 May 1994; revised version received 24 June 1994 Abstract Internucleosomal cleavage of DNA has often been regarded as the biochemical hallmark of apoptosis. We now demonstrate in isolated rat liver nuclei that DNA is initially cleaved into 2700, 200-250 kbp and 30-50 kbp fragments via a multi-step process, which is activated by Mg*+ and Mg*‘+Ca” but not by Ca2’ alone. The subsequent intemucleosomal cleavage requires both cations. These findings demonstrate that a key event in the apoptotic process is the fragmentation of DNA into large kbp fragments by either a Mg”-dependent process (which can be potentiated by Ca”) and/or by a Ca*‘/Mg*’ activated endonuclease(s). Key words: Apoptosis; DNA fragmentation; Magnesium; Endonuclease 1. Introduction that the formation of large fragments of DNA represents a much earlier event in the apoptotic process. In support Two classical morphological features of apoptosis are of this conclusion, it has been shown that isolated hepa- the condensation of chromatin and its margination at the tocytes undergoing apoptosis with TGF-B, treatment ex- nuclear boundary [l].
    [Show full text]
  • Accelerated Apoptotic Dna Laddering Protocol
    Accelerated Apoptotic Dna Laddering Protocol Is Arnoldo honest or edified after melancholy Silvain shove so underhand? Barrie is painted and Merillbeautifies folio streakilyhis florence while map scorpaenoid snort mathematically. Marchall subverts and incarcerate. Masturbatory and farraginous Sem of the case of apoptotic dna ladder covered in Friesel RE, Maciag T: Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. Handbook of Models for Human Aging. Chemical shearing generates randomly distributed fragment lengths visible as a smear of DNA below the peak fragment length. This does not be accelerated and needs further biochemical hallmarks of accelerated apoptotic dna laddering protocol as alcohols or varicella patients and acceptance criteria. First, on one end of the cascade, we have shown that both RAR and RXR need to be stimulated by retinoic acid to trigger apoptosis in this cell line. PHENIX PCR Enzyme Guide PHENIX offers a broad line of premium quality PCR Enzymes. All previously published articles are available through the Table of Contents. Nanopore sequencing theoretically is limited by the input fragment length, there is still a need to assess DNA integrity for quality management purposes rather than rely on the read length distribution generated by sequencing with the nanopore. XL transgenes and photoreceptor degeneration. Apoptotic or nonapoptotic cells suspended in saline containing the detergent and serum proteins, however, are fragile and their pipetting, vortexing or even shaking the tube containing the suspension, causes cell lysis and release of the cell constituents into solution. Heuristics and computational intelligence methods are combined to exploit their respective benefits. Mechanism of lead neurotoxicity. For detecting the active form of Bax, tissues or cells were lysed in CHAPS buffer containing protease inhibitors.
    [Show full text]
  • Application: Detection of the Early Stages of Apoptosis Using Apopladder Ex™
    ApopLadder Ex™ (Cat.# MK600) Application: Detection of the Early Stages of Apoptosis Using ApopLadder Ex™ Apoptosis is characterized by fragmentation of chromosomal DNA into multiples of approximately 180 nt, corresponding to nucleosome fragments. This fragmentation process is also referred to as DNA laddering. The ApopLadder Ex Kit allows selec- tive extraction of small, fragmented DNA from apoptotic cells while minimizing chromatin contamination. Using a fluorescent nucleic acid dye such as SYBR® Green I, DNA fragments purified using ApopLadder Ex can be quantified, providing a sensitive method of apoptosis analysis. This application note illustrates the use of ApopLadder Ex and SYBR Green I quantification of DNA fragmentation for the de- tection of the early stages of apoptosis in mouse and human cell lines. Methods P3U1 (murine myeloma cell line) cells were treated for 20 hours with various concentrations of actinomycin D. HL60 (human promyelocytic leukemia cell line) cells (3x105 cells) were treated with 1 μM staurosporine. Apoptosis was analyzed by trypan blue staining and/or analysis of DNA fragmentation using ApopLadder Ex (Cat. # MK600). Results In general, the permeability of the cell membrane increases during late apoptosis, and apoptotic cells can be visualized by trypan blue staining. However, DNA fragmentation occurs early in apoptosis, often before changes in cell membrane perme- ability occur. We hypothesized that the highly sensitive quantitative detection possible with ApopLadder Ex could be used to detect early stages of apoptosis. In P3U1 cells, trypan blue staining indicated an increase in apoptosis when cells were treated with 30 ng/ml actinomycin D (Figure 1). In contrast, in these same cells, an increase in apoptosis (as indicated by an increase in fluorescence intensity) was detected with treatment of as little as 5 ng/ml actinomycin D when fragmented DNA was extracted with ApopLadder Ex and quantified with SYBR Green I.
    [Show full text]
  • DNA Laddering Kit
    DNA Laddering Kit Item No. 660990 www.caymanchem.com Customer Service 800.364.9897 Technical Support 888.526.5351 1180 E. Ellsworth Rd · Ann Arbor, MI · USA TABLE OF CONTENTS GENERAL INFORMATION GENERAL INFORMATION 3 Materials Supplied Materials Supplied 4 Safety Data 4 Precautions Item Number Item Quantity/Size Storage 4 If You Have Problems 4 Storage and Stability 660991 Lysis Buffer 4 vials/1.2 ml -20°C 5 Materials Needed but Not Supplied 660992 10% SDS 1 vial/0.48 ml -20°C INTRODUCTION 6 Background 6 About This Assay 660993 Enzyme A 1 vial/0.48 ml -20°C ASSAY PROTOCOL 8 Performing the Assay 660994 Enzyme B 1 vial/0.48 ml -20°C RESOURCES 10 Troubleshooting 660995 Precipitating Reagent 3 vials/1.04 ml -20°C 10 References 11 Notes 660996 Gel-Loading Buffer (6X) 1 vials/0.48 ml -20°C 11 Warranty and Limitation of Remedy If any of the items listed above are damaged or missing, please contact our Customer Service department at (800) 364-9897 or (734) 971-3335. We cannot accept any returns without prior authorization. WARNING: THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR ! HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE. GENERAL INFORMATION 3 Safety Data Materials Needed But Not Supplied This material should be considered hazardous until further information becomes 1. 1.5 ml microcentrifuge tubes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash 2. 37°C incubator thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.
    [Show full text]
  • Apoptotic DNA Laddering Kits Are Used to Assay Cells and Tissues for Apoptosis by Detecting Internucleosomal DNA Fragmentation and Displaying DNA Laddering
    TACS™ DNA Laddering Kit Apoptosis Detection Kit catalog number: TA4633 Colorimetric 20 tests FOR RESEARCH USE ONLY NOT FOR USE IN DIAGNOSTIC PROCEDURES TABLE OF CONTENTS Contents Page PRINCIPLE OF THE ASSAY 2 REAGENTS AND MATERIALS . .2 MATERIALS REQUIRED BUT NOT SUPPLIED 3 Reagents . 3 Equipment 3 PROCEDURES 3 DNA Isolation . 3 Colorimetric Labeling and Detection 5 RESULTS . 6 TROUBLESHOOTING GUIDE 7 APPENDICES . 8 DNA Extraction from Tissue Samples 8 Casting TreviGel™ 500 . 8 Buffer Compositions 9 WARNINGS . 9 MANUFACTURED FOR AND DISTRIBUTED BY: R&D Systems, Inc. TELEPHONE: (800)343-7475 614 McKinley Place N.E. (612)379-2956 Minneapolis, MN 55413 FAX: (612)379-6580 United States of America E-MAIL: [email protected] R&D Systems Europe 4 - 10 The Quadrant TELEPHONE: (0)1235 551100 Barton Lane FAX: (0)1235 533420 Abingdon, Oxon OX14 3YS E-MAIL: [email protected] United Kingdom R&D Systems GmbH FREEPHONE: 0800 909 4455 Borsigstrasse 7 TELEPHONE: 06122 90980 65205 Wiesbaden-Nordenstadt FAX: 06122 909819 Germany E-MAIL: [email protected] PRINCIPLE OF THE ASSAY TACS Apoptotic DNA Laddering Kits are used to assay cells and tissues for apoptosis by detecting internucleosomal DNA fragmentation and displaying DNA laddering. DNA laddering is one of the hallmark events that confirms apoptosis. During apoptosis, endonucleases produce double-stranded breaks generating DNA fragments. These DNA fragments are isolated from cells or tissues using the optimized TACS DNA isolation reagents that inactivate endogenous nucleases and rapidly recover high and low molecular weight DNA. The isolated DNA is labeled with biotinylated deoxynucleotides. The labeled DNA is then size-fractionated by gel electrophoresis.
    [Show full text]
  • Complete 1110 with Extra Posters
    European Cell Death Organization 15 (ECDO) The Jožef Stefan Institute, Ljubljana, October 26-31, 2007, Portoroz, Slovenia ___________________________________________________________________________ Programme and Book of Abstracts This publication is available at the conference website http://www.ecdo.eu/portoroz/index.html Supported by EC within the framework of the Marie Curie ___________________________________________________Conferences and Training Courses ________________________ No responsibility is assumed by the publisher for any injury and/or damage to persons or property resulting either directly or indirectly from material contained within this book. Supported by EC within the framework of the Marie Curie ___________________________________________________Conferences and Training Courses ________________________ 15 th Euroconference on Apoptosis Organisation Local Organisation Boris Turk Department of Biochemistry, Molecular and Structural Biology J. Stefan Institute Jamova 39 SI-1000 Ljubljana, Slovenia Tel. +386 1 477 3772 Fax. +386 1 477 3984 e-mail: [email protected] ECDO Scientific Committee Wilfried Bursch Institute of Cancer Research, Medical University of Vienna, Vienna, Austria Klaus-Michael Debatin University Children's Hospital, Ulm, Germany Wim Declercq VIB/Ghent University, Ghent, Belgium László Fésüs University of Debrecen, Debrecen, Hungary Simone Fulda University Children's Hospital, Ulm, Germany Marie-Lise Gougeon Institut Pasteur, Paris, France Marja Jäättelä Institute for Cancer Biology, Danish Cancer Society,
    [Show full text]
  • Analysis of Atresia in Equine Follicles Using Histology, Fresh Granulosa Cell Morphology and Detection of DNA Fragmentation H
    Reproduction (2003) 125, 417–423 Research Analysis of atresia in equine follicles using histology, fresh granulosa cell morphology and detection of DNA fragmentation H. G. Pedersen1,E.D.Watson1 and E. E. Telfer2 1Department of Veterinary Clinical Studies, University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Midlothian EH25 9RG, UK; and 2Institute of Cell and Molecular Biology, University of Edinburgh, Darwin Building, Mayfield Road, Edinburgh EH9 3JR, UK Follicular atresia has been examined previously by various correlated (P < 0.02) with 20 of 22 follicles (91%) receiv- biochemical and histological methods. The aim of this ing corresponding classifications with the two methods. study was to compare, for the first time, detection of No follicles with granulosa cell apoptosis as detected by granulosa cell apoptosis by biochemical DNA analysis biochemical DNA analysis were histologically viable, but and microscopic examination of fresh granulosa cell some of the histologically early atretic follicles did not morphology with the established method of detecting display DNA laddering. Stereomicroscopic evaluation of atresia by histology in equine follicles. DNA extracted morphology of the fresh granulosa cells was significantly from granulosa cells was examined by staining with correlated (P < 0.001) with the histological findings, with ethidium bromide and end-labelling with [32P]dideoxy-ATP, 29 of 33 follicles (88%) receiving corresponding clas- which labels the free 3-end of DNA fragments. In 25 of sifications. There was a potential error in determining 26 follicles (96%) there was agreement between end- follicle health by biochemical DNA analysis only, as both labelling and staining of DNA with ethidium bromide histologically early and late atretic follicles in some cases (P < 0.001).
    [Show full text]